

## BRAIN TUMOUR GROUP

Chair: Michael Weller, Zurich

Secretary: Jaap Reijneveld, Amsterdam

<http://www.eortc.org/research-groups>

STEERING COMMITTEE MEETING  
October 10, 2018 [9:00 – 11:00]  
EANO Conference Center Stockholm  
Room C1-C3

### Agenda

Invited:

Anna Berghoff (YNO), Amelie Darlix (YNO), Frederic Dhermain (Treasurer), Linda Dirven (CC), Beatrice Fournier (HQ), Pim French (CC), Jens Gempt (YNO), , Thierry Gorlia (HQ), Peter Hau (PI), Roger Henriksson (EANO), Sarah Nuyens (HQ), Emilie Le Rhun (CC, PI), Matthias Preusser (CC, PI), Eva Razis (CC), Jaap Reijneveld (Secretary), Patrick Roth (PI), Corinna Seliger (YNO), Marion Smits (CC), Mehdi Touat (YNO), Martin van den Bent (PI), Maureen Vanlancker (HQ), Guillaume Vogin (YNO), Tina Verschuere (HQ), Damien Weber (PI), Michael Weller (Chair, PI), Tobias Weiss (YNO), Wolfgang Wick (Past-Chair, PI), Laurien Vancleef (HQ)

Absent:

	AGENDA	
9.00-9.10 h	<b>Welcome &amp; Report of the Chair</b>	MW
9.10-9.30 h	<b>Brief updates from the committees &amp; nomination of new committee chairs</b>	
	Pathology & Translational research	PF
	Quality assurance	ER
	Quality of life	LD
	Imaging	MS
	Meningioma	MP
	CNS metastases	ELR
9.30-9.50 h	<b>Current issues regarding completed clinical trials</b>	
	22033-26033: RT vs TMZ in grade II gliomas	TG
	26042: RT for meningioma	DW
	26053-22054: RT vs RT/TMZ in WHO grade III glioma,	MvdB

	CATNON	
	26101: CCNU vs BEV→CCNU vs CCNU→BEV vs BEV+CCNU, Phase II	WW
	26101: CCNU vs BEV/CCNU, Phase III	WW
	26062-22061: RT vs RT/TMZ in glioblastoma in the elderly	TG
	26091: TMZ vs BEV/TMZ in recurrent grade II/III glioma, TAVAREC	MvdB
	1320: Trabectedin for meningioma	MP
	1410: ABT-414 vs ABT-414/TMZ vs CCNU or TMZ in recurrent glioblastoma	MvdB
9.50-10.10 h	<b>Ongoing clinical studies</b>	
	1308: RT for meningioma ROAM	MP
	1419: Long-term survival in glioblastoma	MW
	1608: TG02 plus RT or TMZ in newly diagnosed glioblastoma or AA in the elderly or TG02 alone in recurrent glioblastoma/AA	ELR
	1709: Marizomib in newly diagnosed glioblastoma	PR
10.10-10.30 h	<b>Planned clinical trials</b>	
	26081: RT/PCV vs RT/TMZ in oligodendroglioma, CODEL	WW
	1634: Medulloblastoma	PH
	1635: wait-and-see or treat in lower grade glioma, I-WOT	MvdB
	1746: Meningioma umbrella trial (MERGE)	MP
	1807: SRS plus IO versus IO alone for NSCLC brain metastasis	ELR
10.30-10.45 h	<b>Update on planned meta- and secondary analyses</b>	
	RP 1230 NOA-08 Nordic Cooperation (plus 26062)	TG
	RP 1515 CODAGLIO QOL	JR
	RP 1542 Primary and recurrent glioblastoma	PF
	RP 1654 MGMT	MH
	RP 1661 Central pathology review	MK
	RP 1662 CENTRIC/CORE imaging projects	MW
	RP 1663 Metformin	PH
	RP 1664 Temporal muscle thickness	MP
	RP 1665 Potassium channel antagonists	TG
	RP 1719 Myelosuppression	TG
	RP 1721 QOL / cognition in long-term oligo patients	JR
	RP 1759 AYA/TYA project	TG
	RP 1803 Act IV transfer tissue bank	MW
	RP 1808 Levetiracetam and toxicity	TG
10.45-11.00 h	<b>Any other business</b>	
	Next BTG SC Meeting: during EGAM, March 14 <sup>th</sup> 2019, Brussels, Belgium	
	Next BTG SC Meeting: March 14, 2019, 09.00-12.00 h EGAM, Brussels, Belgium	